R. Dent, M. Trudeau, K. I. Pritchard, W. M. Hanna, H. K. Kahn, C. A. Sawka, L. A. Lickley, E. Rawlinson, P. Sun and S. A. Narod, “Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence,” Clinical Cancer Research, Vol. 13, No. 15, 2007, pp. 4429-4434. doi:10.1158/1078-0432.CCR-06-3045
 B. P. Schneider, E. P. Winer, W. D. Foulkes, J. Garber, C. M. Perou, A. Richardson, G. W. Sledge and L. A. Carey, “Triple-Negative Breast Cancer: Risk Factors to Potential Targets,” Clinical Cancer Research, Vol. 14, No. 24, 2008, pp. 8010-8018. doi:10.1158/1078-0432.CCR-08-1208
 S. Verma, N. S. Wong, M. Trudeau, A. Joy, J. Mackey, G. Dranitsaris and M. Clemons, “Survival Differences Observed in Metastatic Breast Cancer Patients Treated with Capecitabine When Compared with Vinorelbine after Pretreatment with Anthracycline and Taxane,” American Journal of Clinical Oncology, Vol. 30, No. 3, 2007, pp. 297-302. doi:10.1097/01.coc.0000258125.97090.3f
 F. Kassam, K. Enright, R. Dent, G. Dranitsaris, J. Myers, C. Flynn, M. Fralick, R. Kumar and M. Clemons, “Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design,” Clinical Breast Cancer, Vol. 9, No. 1, 2009, pp. 29-33. doi:10.3816/CBC.2009.n.005
 B. N. Rexer, R. Ghosh and C. L. Arteaga, “Inhibition of PI3K and MEK: It Is All about Combinations and Biomarkers,” Clinical Cancer Research, Vol. 15, No. 14, 2009, pp. 4518-4520. doi:10.1158/1078-0432.CCR-09-0872
 J. S. Ross, J. A. Fletcher, G. P. Linette, J. Stec, E. Clark, M. Ayers, W. F. Symmans, L. Pusztai and K. J. Bloom, “The Her-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy,” Oncologist, Vol. 8, No. 4, 2003, pp. 307-325. doi:10.1634/theoncologist.8-4-307
 A. K. Swayampakula, V. Gadiyaram and J. Abraham, “Serum Levels of HER2/neu, a Potential Alternative to Tissue Specimen Levels in the Management of Metastatic Breast Cancer: A Case Report and Literature Review,” Community Oncology, Vol. 6, No. 8, 2009, pp. 362-364.
 R. Iosifidou, G. Galaktidou , A. Ananiadis, N. Bladika, F. Patakiouta and A. Bousoulegas, “VEGF-A, VEGF-C, VEGF-R2, EGFR and HER2 in Serum Plus EGFR in Tissue of Patients with Triple-Negative Breast Cancer,” Breast Cancer Research, Vol. 11, 2009, p. 13.
 Y. Sawada, T. Fujii, H. Takahashi, G. Yokoyama, R. N. Matsubayashi, Y. Inoue, N. Uesugi, S. Momosaki, U. Toh and K. Shirouzu, “A Case of Triple Negative Chest Wall Recurrent Breast Cancer Treated with Capecitabine and Docetaxel Combination Therapy (XT Therapy),” Journal of Cancer Chemotherapy, Vol. 36, No. 5, 2009, pp. 815-817.
 G. Zhang, M. A. Park, C. Mitchell, H. Hamed, M. Rahmani, A. P. Martin, D. T. Curiel, A. Yacoub, M. Graf, R. Lee, J. D. Roberts, P. B. Fisher, S. Grant and P. Dent, “Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation,” Clinical Cancer Research, Vol. 14, No. 17, 2008, pp. 5385-5399. doi:10.1158/1078-0432.CCR-08-0469
 T. Samuel, W. Fiskus, C. Buser and K. Bhalla, “A Novel Combination Therapy with Histone Deacetylase Inhibitor and Aurora Kinase Inhibitor for ‘Triple Negative’ Breast Cancers,” Cancer Research, Vol. 69, No. 2, 2009, p. 401. doi:10.1158/0008-5472.SABCS-401